Chronic Lymphocytic Leukaemia (CLL) is an incurable disease and although it is usually responsive to chemotherapy, treatment is reserved for symptomatic patients with extensive lymphadenopathy, sweating or weight loss. In most patients treatment with alkylating agents alone will produce relief of symptoms accompanied by a reduction in lymphadenopathy and a fall in peripheral blood and bone marrow lymphocyte infiltration (Gale & Foon, 1985) . Although a complete remission may be induced in a small proportion of patients, it is probably not possible to eradicate the disease even with intensive chemotherapy. In many patients increasing resistance to chemotherapy leads ultimately to uncontrollable tumour cell proliferation and disease progression; mortality, however, is often attributed to infection, the risk of which may be increased by treatment.
The potential value of predictive drug sensitivity assays in the selection of cytotoxic chemotherapy has been recognised for many years (Weisenthal, 1981) . This would be of particular benefit when the risks of therapy have to be carefully weighed against the possible benefits. The value of several different cytotoxicity assays has been investigated in patients with lymphoproliferative disorders (Veerman & Pieters, 1990) ; low plating efficiency has limited the value of clonogeneic assays in these disorders, while direct cytotoxicity assay have produced some promising results (Weisenthal et al., 1986; Twentyman et al., 1989; Bosanquet, 1991) .
The purpose of the present study was to determine whether the uptake of a DNA precursor (3H-thymidine) by CLL lymphocytes was sensitive to the effects of chlorambucil in vitro and whether such an approach could be used to predict drug sensitivity in these patients.
Subjects and methods

Subjects
Twenty-four patients, 14 male and ten female, with CLL were studied. Six of these had received previous treatment and 18 remained untreated at the start of the study. Disease stage was identified according to the classification of Binet et al., (1981) technique, which was maintained throughout. Ten ml of heparinised blood were added to 14 ml of phosphate buffered saline (PBS) pH 7.2 and 8.0 ml volumes of this dilution were layered onto 3.0 ml of a solution of ficoll and sodium diatrizoate (Histopaque-1077, Sigma Chemical Co., Poole, Dorset, UK) in conical centrifuge tubes and spun at 400 g for 30 min. The upper layers were aspirated to within 0.5 cm of the opaque interface layers containing the lymphocytes and discarded. The opaque interface layers were transferred into clean conical centrifuge tubes and 10 ml PBS were added to each and the whole contents mixed by inversion. The tubes were then centrifuged at 250 g for O min and the supernatants discarded. Erythrocyte contamination was removed by lysis by the addition of 10 ml of 0.87% ammonium chloride solution to the tubes which were left standing for 5 min at room temperature and then centrifuged at 250 g for 10 min. The ammonium chloride solution was discarded and the pellets washed with 10 ml PBS and again centrifuged at 250 g for 10 min. All the lymphocytes separated from an individual patient or normal subject were then pooled prior to a final wash.
Lymphocyte proliferation
All cultures were undertaken using Eagle's Minimum Essential Medium (Gibco Ltd, Paisley, UK) supplemented with 0.22% sodium bicarbonate, 5% foetal calf serum, 10,000 iu 100ml-1 sodium benzyl penicillin and 5,000 ig lOOml-' streptomycin. Culture solutions were sterilised by filtration through 0.2 i membrane filters. The separated lymphocytes were resuspended in this medium and the concentration adjusted to 1 x 106 cellsml-'.
Cultures were performed in 2 ml microtubes (Sarstedt Ltd, Leicester, UK). Preliminary studies had shown that the addition of 0.2 ml of autologous serum to 1.0 ml of lymphocyte suspension produced optimal culture conditions. Fifty ;LI of a solution of either 0.4 pg ml-' pokeweed mitogen (PWM) in PBS or 4 jig ml-' phytohaemagglutinin (PHA) (Bosanquet, 1985) solutions were never refrozen. One aliquot was thawed on the day of use and diluted further in PBS to produce concentrations of 0.5-10 tgml-' in the cultures. In some instances additional stock solution was used to achieve a higher final concentration.
All cultures were incubated at 37°C in 5% carbon dioxide in humidified air for 66 h. Two fsCi (0.074 MBq) 3H-thymidine (Amersham International Plc, Amersham, Bucks, UK) in 0.1 ml PBS were then added and the cultures incubated for a further 24 h.
Cell harvest
Lymphocytes were harvested by filtration through 2.5 cm glass microfibre filter discs (Whatman Labsales Ltd, Maidstone, Kent, UK) using Whatman 3-piece filter funnel units attached to a suction pump. The contents of each tube were mixed and pipetted onto a filter disc; the tubes were washed out three times with 2.0 ml cold PBS and the washings filtered. The discs were finally washed through twice with 5.0 ml cold PBS. Each disc was removed from its filter unit and left to dry overnight at room temperature in a 20 ml scintillation vial (Canberra Packard Ltd, Pangbourne, Berks, UK).
Scintillation counting
Five ml of scintillation fluid (Insta-Gel, Canberra Packard Ltd, Pangbourne, Berks, UK) were added to each vial and after capping and shaking all vials were chilled at 4°C for 45 min in the dark. Counting was performed in an Intertechnique SL 30 liquid scintillation spectrometer.
The mean of each triplicate set of readings was calculated with the background counts subtracted. The percentage 3H-uptake in each culture was calculated taking the uptake in the control cultures without chlorambucil as 100%.
Results
A typical dose-response curve obtained using the lymphocytes from a normal subject is shown in Figure 1 dose-response curves obtained from one previously treated and from one untreated patient.
There was a linear inverse relationship between the log 3H-thymidine uptake by the normal or the neoplastic lymphocytes in culture and the chlorambucil concentration to which they were exposed. The latter was examined over the range 0.5-5pgml-1 for the normal lymphocytes, 0.5-7jig ml-' for the untreated patients' lymphocytes and 0.5-25Ag ml-' for the treated patients' cells in order to achieve a thymidine uptake inhibition in excess of 70%. Data points were fitted by least squares to a linear function of chlorambucil concentration against log percentage lymphocyte 3H-thymidine uptake. The slope of each curve and the chlorambucil concentration required to achieve a 50% growth inhibition (ID50) were calculated in each case. Comparisons of the means for each group were made using the Mann-Whitney non-parametric test and of repeat assays performed in the same patient using the Wilcoxon Signed Rank Test.
The mean (± s.d.) ID50 for normal lymphocytes was 1.7 ± 0.5 (range 0.9-2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718 Chlorambucil concentration ,ug ml-1 Figure 2 The effect of chlorambucil on 3H-thymidine uptake by mitogen-stimulated CLL lymphocytes; 0, untreated patient, *, treated patient.
6.0 Figure 1 The effect of chlorambucil on 3H-thymidine uptake by normal mitogen-stimulated lymphocytes.
-0.049 to -0.146) and this is significantly lower than that for the normal cells (U = 13.5, P = 0.0003). (Figure 3) . In two untreated patients, who have still not required any treatment, the ID50 was greater than 4 jig ml-'.
Five patients (all stage C) previously found to be refractory to treatment including alkylating agents, anthracyclines and cortico-steroids were investigated. Their mean ( ± s.d.) ID50 was 1.1 ( ± 6.9) fig ml-and this was significantly higher than that of the untreated patients (U = 3.0, P= 0.002), and that of the responsive patients (Figure 3 , U = 0, P = 0.003). Similarly the slope of the dose:response curves (mean + s.d., 0.042 ± 0.028) for these patients was significantly lower (U = 9.0, P = 0.008) than that of the untreated patients. Each of these patients initially received treatment with chlorambucil and all have subsequently died after an interval of between 4 and 10 months after their lymphocytes were studied.
In ten instances (six patients) lymphocyte sensitivity was studied before and after the patient had received treatment with chlorambucil. On six of these occasions treatment was given for the first time, but in the remainder the patients had received treatment on at least one previous occasion. In all instances, apart from in one patient with continously responsive disease, the post-treatment ID50 was greater than the pretreatment level (Table IV, Figure 4 ), although in one instance this was by only 2.4%. This increase was highly significant (W = -51.0, P = 0.006). In several patients serial studies were undertaken and an increasing ID50 was associated with increasing clinical resistance to therapy. A typical example is shown in Figure 5 .
Discussion
Chlorambucil is a bifunctional alkylating agent with cytotoxic activity dependent on the formation of cross links between complementary strands of DNA (Silber et al., 1989 Leukaemia, 1986; Monserrat et al., 1985) . Furthermore most CLL patients will ultimately become resistant to the effect of treatment and the management of resistant disease has proved to be difficult and hazardous; many patients will succumb to intercurrent infection, the risk of which may be enhanced (Weisenthal et al., 1986; Twentyman et al., 1989) and have been shown to be of predictive value in the management of these disorders (Bosanquet, 1991; Hansen et al., 1991) . The MTT assay, which depends on the ability of viable cells to reduce a tetrazolium salt, and dye exclusion assays are the most widely studied of these. These assays undoubtedly have the advantage of simplicity, speed, lack of dependence on cell division and application to a wide variety of tumours and drugs.
The present study, however, examines sensitivity by the effect of the drug on precursor incorporation into the DNA of mitogen-stimulated CLL lymphocytes. Robert et al. (1978) and Isakovic and Lenert (1987) have demonstrated that CLL cells are responsive to PHA and to PWM. In the present study stimulation of DNA synthesis by PWM produced sufficient 3H-thymidine uptake to produce satisfactory dose:response curves except in two subjects in whom it was necessary to use PHA as the mitogen. Both of these patients were included with those patients previously found to be refractory to treatment and their data not used in the predictive part of the study. In general, however, there was a much (Bosanquet et al., 1983; Bosanquet, 1991 showed an increase in cellular resistance to chlorambucil which appears to be maintained in vivo for many months after withdrawal of treatment and into the terminal phase of the disease.
The present data do not provide any indication of the mechanism of drug resistance in these patients. Increased activity of a membrane efflux pump mechanism has been identified in some patients with leukaemia (Kuwazuru et al., 1990) , but this is not thought to be relevant in chlorambucil resistance. Bank et al. (1989) have shown an equally rapid cytoplasmic uptake of chlorambucil in chemotherapy-resistant and chemotherapy-sensitive CLL cells. Drug neutralisation by increased intracellular glutathione (GSH) levels (Suzukake et al., 1983) has been suggested Silber et al. (1989) found no difference in the GSH content of CLL lymphocytes compared to that of normal lymphocytes, although they did find intracellular GSH levels unstable in CLL cells in the presence of chlorambucil. In contrast to the present finding, these workers found normal lymphocyte viability less sensitive to the effects of chlorambucil than were CLL lymphocytes. Johnston et al. (1990) 
